This week in psychedelic business news: Enveric Biosciences uses AI to identify viable psychedelic drug candidates; Novamind launches end-of-life palliative care program; and PharmaTher tests ketamine to treat Parkinson’s Disease.
“This designation not only expedites our regulatory, clinical, and product development plans but also validates our belief in the potential of ketamine,” says PharmaTher CEO Fabio Chianelli.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.